Jordyn Sava is an editor for Targeted Oncology.
The effects of chemotherapy-induced myelosuppression for extensive-stage small cell lung cancer were assessed in a new study which used a real-world community oncology setting.
In an interview with Targeted Oncology, Ajay Nooka, MD, discussed findings from the phase 3 KarMMa-3 trial and the use of ide-cel for the treatment of patients with relapsed/refractory multiple myeloma.
Results from the EARLY-MYO-BC trial assessing the pyrotinib’s cardiac impacts may help researchers select an appropriate anti-HER2 treatment when managing patients with HER2-positive breast cancer.
Mirvetuximab soravtansine is being assessed in combination with bevacizumab as a treatment for patients with folate receptor-alpha-positive recurrent platinum-sensitive ovarian cancer.
Topline data from part A of the THIO-101 trial showed that patients treated with THIO plus cemiplimab had mild toxicities, including grade 1 fatigue and muscle pain, and 1 case of grade 3 nausea among patients with non–small cell lung cancer.
A phase 2, open-label clinical trial is evaluating treatment with QBS72S in patients with histologically-confirmed breast cancer that has developed brain metastases after a prior cytotoxic chemotherapy regimen.
In a study performed at MD Anderson Cancer Center, there was no significant overall survival impact in patients with anaplastic thyroid cancer who had prior differentiated thyroid cancer, concomitant differentiated thyroid cancer, and prior non thyroid cancers.
TP-1287, an investigational oral phosphate prodrug of the CDK9 inhibitor alvocidib, has been granted an orphan drug designation by the FDA for patients with Ewing sarcoma.
CB-011 has received a fast track designation from the FDA for the treatment of relapsed/refractory multiple myeloma and is being investigated in the ongoing CaMMouflage study.
The phase 3 Karmma-3 trial of ide-cel in patients with triple-class-exposed relapsed/refractory multiple myeloma generated significantly improved progression-free survival and overall response rates vs standard regimens.
A first-in-human study is assessing the safety, efficacy, and pharmacokinetics of DK210 as a monotherapy and in combination with immunotherapy, radiotherapy, or chemotherapy for patients with EGFR-expressing solid tumors.
In the KEYNOTE-045 and KEYNOTE-052 trials, pembrolizumab continued to led to durable responses with no new safety signals after 5 years.
With 1.5 years of follow-up, the confirmed objective response rate was 92.5% among patients who were ROS1 tyrosine kinase inhibitor-naïve and 52.6% in crizotinib-pretreated patients in the phase 2 TRUST-I trial.
Neither the LEAP-003 nor LEAP-017 studies study showed survival benefit with pembrolizumab plus lenvatinib for patients with melanoma or colorectal cancer.
In an interview with Targeted Oncology, Bridget Koontz, MD, discussed burnout and its importance in experts treating patients with cancer.
The investigational new drug, SynKIR-110, has received a fast track designation from the FDA for patients with mesothelioma and is continuing to be evaluated in a phase 1 trial.
Multiple trials and techniques have evaluated treatment with HLX02 compared with trastuzumab. Now, the FDA has accepted the biologics license application HLX02 for patients with HER2-overexpressing metastatic breast cancer, breast cancer, gastric cancer, and gastroesophageal junction adenocarcinoma.
The largest registrational study of immune checkpoint inhibitor therapy in relapsed/refractory extranodal natural killer/T-cell lymphoma showed potent and durable antitumor activity with sugemalimab.
Data from a phase 1/2 study of BDC-1001 alone or with nivolumab supports selection of a recommended phase 2 dose, advancement of further phase 2 studies, and assessment of the agent in combination with pertuzumab.
Results from the phase 2 PHAROS trial of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic non–small cell lung cancer has led the FDA to accept supplemental new drug applications for the agents. Further data will be presented at an upcoming medical meeting.
In an interview with Targeted Oncology, Neal D. Shore, MD, FACS, gave an overview of previous and updated findings from the ARAMIS trial for patients with nonmetastatic castration-resistant prostate cancer.
Data from an analysis of the combined NRG-RTOG 0630/9514 trials show that pathologic complete response can be used as a prognostic factor for clinical outcomes in future research of patients with soft tissue sarcoma.
Enfortumab vedotin plus pembrolizumab is now an FDA approved treatment based on positive phase 1b/2 findings.
The next-generation anthracycline Annamycin has been administered to the first patient with relapsed/refractory acute myeloid leukemia in combination with cytarabine in a phase 1/2 study.
Here is a look back at the FDA happenings from March 2023.
A phase 1/2 trial investigating GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas will begin following the acceptance of an investigational new drug application for the agent.
Based on findings from a phase 1 trial, osemitamab has gained an orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.
The FDA has granted a fast-track designation for RRx-001 and accepted the investigational new drug application for a phase 2b trial of severe oral mucositis in chemotherapy- and radiation-treated patients with head & neck cancer.
In an interview with Targeted Oncology, Craig Sauter, MD, discusses available treatments for patients with central nervous system lymphoma and research that will provide more developments moving forward in this space.
In an interview with Targeted Oncology, Raajit K. Rampal, MD, PhD, discussed the currently approved JAK inhibitors used to treat patients with myelofibrosis, and exciting movements in the field.